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ABSTRACT
Monoclonal antibodies (mAb) have become an
effective treatment strategy for hematologic
malignancies. CD30 is a rational target for
therapy due to its limited expression on normal
tissues and the strong and uniform expression
on malignant cells in classical Hodgkin’s
lymphoma (cHL) and anaplastic large-cell
lymphoma (ALCL). Brentuximab vedotin, an
anti-CD30 antibody-drug conjugate, utilizes the
targeting properties of mAb to deliver a cytotoxic
agent inside the malignant cell. Brentuximab
vedotin has significant clinical activity in
patients with relapsed or refractory cHL and
relapsed or refractory ALCL, and has the
potential to represent a significant advance in
modern oncology.
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INTRODUCTION
CD30 is a prosurvival receptor, which belongs
to the tumor necrosis factor receptor (TNFR)
superfamily [1]. Although CD30 was recognized
in the early 1980s as an important marker for
Hodgkin Reed–Sternberg cells (HRS), it is now
known that CD30 is also expressed in other B
cell and T cell non-Hodgkin’s lymphomas
(NHL), as well as in a normal subset of
activated B- and T-natural killer (NK) cells and
activated monocytes [2].
Two lymphoid neoplasms are characterized
by strong and uniform expression of CD30:
Hodgkin’s lymphomas (HL) and anaplastic
large cell lymphoma (ALCL). HL accounts
for approximately 11% of all malignant
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lymphomas, and is further classified in two
major subtypes: classical (cHL) and nodular
lymphocyte predominant HL [3]. In cHL,
modern treatment combining chemotherapy
and radiotherapy can cure the majority of
patients. However, 10–30% of patients may
progress or relapse, depending on baseline risk
factors and type of treatment [4]. Up to 50% of
these patients can still be cured with high-dose
chemotherapy and autologous stem cell
transplantation (ASCT). The prognosis of
patients who are primary refractory or relapse
after ASCT is poor, with a median overall
survival (OS) of approximately 2 years,
constituting a highly unmet medical need [5].
Systemic ALCL (sALCL) is an aggressive T cell
lymphoma that represents approximately 2–3%
of all lymphoid neoplasms. ALCL can be further
classified on the basis of the expression of the
anaplastic lymphoma kinase (ALK) protein.
Patients with ALK-positive ALCL and no risk
factors have responses similar or better than
patients with B cell lymphomas when treated
with conventional anthracycline-based
chemotherapy. However, patients with ALK-
negative ALCL tend to have low response rates
and up to 60% of patients may relapse after
front-line therapy [6]. High-dose therapy and
ASCT may result in long-term remission in




Rituximab, an anti-CD20 monoclonal antibody
(mAb), has consistently proved to increase the
response rates and disease-free survival in
almost all B cell neoplasms [8]. The success
of an immunotherapy-based strategy in
lymphomas led to intense research for other
targets for mAbs, including CD30. A number
of anti-CD30 mAbs have been developed,
including SGN-30, MDX-060, and XmAb2513.
SGN-30 (also known as cAC10) is a chimeric
anti-CD30 antibody constructed from the
variable regions of the anti-CD30 murine
monoclonal AC10 and the human gamma 1
heavy chain and kappa light chain constant
regions. In a phase 1 study, 24 patients with
CD30? malignancies, including 21 patients
with HL and 3 patients with CD30? NHL,
were treated with escalating doses of SGN-30.
Treatment was well tolerated and no maximum
tolerated dose (MTD) was reached. However,
although well tolerated, responses were modest:
one patient with cutaneous ALCL achieved a
complete response (CR) and six patients,
including four patients with HL, achieved
stable disease, with durations up to 16 months
[9].
In an open-label, phase 2 study, 79 patients
with recurrent or refractory HL (n = 38) or
sALCL (n = 41) received weekly infusion of
SGN-30 for 6 weeks, with the initial 40
patients receiving 6 mg/kg weekly, and the
latter 12 mg/kg weekly [10]. Although proved
safe, with only mild adverse events, objective
responses were observed only in the ALCL
group, in which two patients achieved a CR
and five patients achieved a partial response
(PR), with response durations ranging from 27
to 1,460? days. No objective responses were
observed in the HL group, and only 11 patients
(29%) achieved stable disease. The role of SGN-
30 in cutaneous ALCL was further tested in a
phase 2 trial [11], showing an overall response
rate (ORR) of 70% (16 of 23 patients).
Since modest responses were observed with
SGN-30 in HL, and based on the synergistic
activity observed in preclinical models when
SGN-30 was combined with cytotoxic agents
active in HL, a phase 2 study explored the
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feasibility and efficacy of SGN-30 in
combination with GVD (gemcitabine,
vinorelbine, and pegylate liposomal
doxorubicin). Initially, 16 patients were
treated with SGN-30 plus GVD, and in a
second portion of the study, patients were
randomized to receive GVD with either
SGN-30 or placebo. However, this trial was
prematurely closed due to an increased
pulmonary toxicity observed in patients
treated with SGN-30 and GVD [12].
MDX-060 is a fully human anti-CD30
immunoglobulin G1j mAb with greater
antibody-dependent, cell-mediated cytotoxicity.
In a sequential phase 1/2 study, 72 patients with
HL (n = 63), ALCL (n = 7), and CD30? T cell
lymphoma (n = 2) were enrolled. MDX-060 was
well tolerated, with no MTD identified. However,
limited single-agent activity was observed, with
only 6 patients with clinical responses and 25
patients with stable disease [13]. The second
generation anti-CD30 antibodies (MDX-1401
and XmAb2513) have modified Fc (fragment,
crystallizable) regions to increase efficacy.
Preliminary results from phase 2 studies show
good tolerability but limited efficacy [14, 15].
BRENTUXIMAB VEDOTIN
Since minimal activity was observed in trials of
first-generation ‘‘naked’’ anti-CD30 antibodies,
and the combination of SGN-30 with cytotoxic
agents resulted in significant toxicity, new
strategies for immunotherapy against CD30
were tested including the development of an
antibody-drug conjugate (ADC).
The combination of the chimeric anti-CD30
antibody cAC10 with monomethylauristatin E
(MMAE), a potent antimitotic agent, led to the
development of brentuximab vedotin [16]. A
protease-cleavable linker was used to attach
MMAE to cAC10, offering significant stability,
with less than 2% release of the drug from the
mAb after 10-day incubation in human plasma
[17]. Brentuximab vedotin has a well defined
structure with an average of four drugs per mAb
and no free MMAE in the drug product.
After targeting the CD30 receptor,
brentuximab vedotin is internalized into the
cells and the peptide linker is subsequently
cleaved by lysosomal enzymes, releasing
MMAE inside the cells. MMAE blocks the
polymerization of tubulin, resulting in G2/M
phase growth arrest and apoptotic death.
In vivo, brentuximab vedotin inhibits
proliferation, induces apoptosis, and complete
tumor regression in mouse xenograft models of
both HL and ALCL, with improved efficacy
relative to the unconjugated antibody [18].
In vivo studies in animals suggest that only a
fraction of MMAE released from the ADC is
metabolized, mainly via oxidation by CYP3A4/
5. The elimination of MMAE occurs both in
urine and feces, the latter being responsible for
72% of the total MMAE recovered. Interestingly,
the elimination of MMAE appears to be limited
by its rate of release from the ADC. There are
currently no studies on dose adjustment for
special populations, such as elderly patients, or
patients with renal or hepatic impairment.
CLINICAL STUDIES IN CD30?
MALIGNANCIES
Phase 1 Studies
In the initial phase 1 dose-escalation study, 45
patients with confirmed relapsed/refractory
CD30? hematologic malignancies (42 patients
with cHL, 2 patients with sALCL, and 1 patient
with CD30? angioimmunoblastic T cell
lymphoma) were enrolled. The median age
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was 36 years and the median number of
chemotherapy regimens was 3, with 73%
of patients having failed a prior ASCT.
Brentuximab vedotin was administered
intravenously every 3 weeks at doses escalating
from 0.1 to 3.6 mg/kg, with no premedication
needed. The MTD for dosing every 3 weeks was
defined as 1.8 mg/kg and the dose-limiting
toxicities were febrile neutropenia, prostatitis,
and hyperglycemia. Other common adverse
events included fatigue, peripheral neuropathy
(PN), nausea, diarrhea, neutropenia, and pyrexia,
but were usually grade 1 or 2 in severity [19].
Objective responses were observed in 17
patients, including 11 CRs. Tumor regression,
assessed by computed tomography, was
observed in 36 of 42 evaluable patients (86%).
Furthermore, 81% of patients with B symptoms
had resolution of symptoms following
treatment, regardless of response status. For
patients receiving the MTD, the ORR was 50%.
In another phase 1 study [20], 44 patients
with relapsed/refractory CD30? malignancies
(38 patients with cHL, 5 patients with ALCL,
and 1 patient with peripheral T cell lymphoma)
were enrolled to receive a different schedule of
brentuximab vedotin, with weekly doses of
0.4–1.4 mg/kg for 3 out of 4 weeks in each
cycle. Significant clinical activity was observed
with tumor regression observed in 85% of all
patients, with a CR rate of 34%. However, in
comparison with the 3 week schedule, there
was a significant increase in neuropathy, with
10% of the patients experiencing grade 3
neuropathy.
Phase 2 Studies
Due to encouraging results in the phase 1 trials,
two separate phase 2 trials were conducted in
patients with cHL and sALCL. In a pivotal,
open-label, single-arm, phase 2 trial, patients
with confirmed diagnosis of relapsed or
refractory HL after ASCT received brentuximab
vedotin at the dose of 1.8 mg/kg intravenously
every 3 weeks for a maximum of 16 infusions
[21]. A total of 102 patients were enrolled with a
median age of 31 years (range, 15–77 years).
Over 70% of patients had primary refractory
disease and 42% had disease refractory to the
most recent therapy, with a median number of
prior therapies of 3.5 (range, 1–13) excluding
ASCT. The ORR was 75%, and 34% of all
patients achieved a CR. Furthermore, tumor
reductions were observed in nearly all patients
(94%). The median duration of response was
6.7 months, and was longer (20.5 months) for
patients who achieved a CR. The estimated
12-month overall survival was 89% and the
estimated median progression-free survival
(PFS) was 5.6 months, although patients
achieving a CR had considerably longer
(21.7 months) PFS. As observed in the phase 1
studies, the most common adverse events were
peripheral sensory neuropathy (42%), nausea
(35%), fatigue (34%), neutropenia (19%),
diarrhea (18%), pyrexia (14%), vomiting
(13%), arthralgia (12%), pruritus (12%),
myalgia (11%), peripheral motor neuropathy
(11%), and alopecia (10%). PN was the most
common adverse effect leading to treatment
discontinuation. However, complete resolution
of all events of peripheral neuropathy was
observed in 50% of the patients [21].
In another multicenter, open-label, phase 2
trial, 58 patients with relapsed or refractory
ALCL after at least one prior therapy with
curative intent [CHOP (cyclophosphamide,
hydroxydaunorubicin, oncovin, prednisone)
in most of patients], were enrolled [22].
Brentuximab vedotin was administered
intravenously once every 3 weeks, for up to
16 doses. The median age was 52 years
(range, 14–76 years) and 72% of patients had
18 Biol Ther (2013) 3:15–23
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ALK-negative disease, with most patients
(62%) being primary refractory to front-line
treatment. The median number of prior
regimens was 2 (range, 1–6), with 26%
patients failing ASCT before enrollment.
Tumor reductions were observed in 97% of
patients, with an ORR of 86%, and 57% of
patients achieving CR. The median duration
of response was 12.6 months for all patients,
and 13.2 months for patients in CR.
The responses were similar for patients
with ALK-negative (ORR 88%, CR 52%) and
ALK-positive (ORR 81%, CR 69%) disease.
The median PFS time was 13.3 months for
responding patients and 14.6 months for
patients in CR. At the time of analysis, the
median OS had not yet been reached, but the
estimated 12-month survival rate was 70%.
Interestingly, this study analyzed subgroups of
patients who had subsequent stem cell
transplantation (SCT). For the 22 patients who
achieved a CR and did not have a subsequent
SCT, the median duration of response was
12.6 months, compared with 13.2 months for
patients who subsequently had an allogeneic
SCT and a median not reached for the five
patients who had a subsequent autologous SCT
in CR [22].
SAFETY PROFILE OF BRENTUXIMAB
VEDOTIN
Generally, outpatient treatment with
brentuximab vedotin is well tolerated. As with
other chimeric mAbs, infusion-related reactions
are observed, but are manageable.
Premedication is usually necessary only for
patients who experienced prior infusion-
related reactions. Other common side effects
include nausea, fatigue, neutropenia, diarrhea,
pyrexia, vomiting, arthralgia, pruritus, myalgia,
and alopecia. Most adverse events are
manageable through standard supportive care
and are typically grade 1 or 2.
PN is the most clinically significant adverse
event associated with brentuximab vedotin
treatment. PN is cumulative and dose-
dependent, consistent with that observed with
other antimicrotubule agents. Most patients
develop sensory neuropathy, characterized by
numbness and tingling of fingers and toes, but
peripheral motor neuropathy was observed in
9% of patients in one of the phase 1 trials. In the
pivotal phase 2 study for HL, 56 patients
experienced PN, and these events were
typically grade 1 and 2; 11% of patients had
grade 3 peripheral neuropathy, and there were
no grade 4 events [21]. Only nine of these
patients had to discontinue treatment.
Similarly, in the ALCL study, 41% of patients
presented with PN, with 12% of patients with
grade 3 severity [22].
Complete resolution of symptoms occurred
in 48% of patients and the median time to
improvement or resolution was 9.9 weeks. For
patients who develop grade 2 or 3 neuropathy,
it is recommended that treatment be withheld
until neuropathy improves to grade 1, and the
dose should then be decreased to 1.2 mg/kg.
Since severe pulmonary toxicity was observed
in the phase 1/2 study of SGN-30 combined with
gemcitabine, vinorelbine, and lyposomal
doxorubicin, there was a concern that
pulmonary toxicity could be observed with
brentuximab vedotin. In a phase 1 study by
Younes et al. [23], the combination of
brentuximab vedotin with doxorubicin,
bleomycin, vinblastine, dacarbazine (ABVD) as
frontline therapy of patients with advanced-stage
cHL resulted in pulmonary toxicity in 7 of 19
patients, leading to a formal warning by the US
Food and Drug Administration (FDA) against the
use of brentuximab vedotin with bleomycin.
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The exact mechanism of pulmonary toxicity
with SGN-30 or brentuximab vedotin when
used in combination with chemotherapy is
not known. In the SGN-30 ? GVD trial, five
patients experienced grades 3–5 pulmonary
toxicities, and were treated with broad-
spectrum antibiotics and concomitant high-
dose steroids. Although an infectious cause
could be proved postmortem in one patient,
there is a possible genetic cause, since distinct
FCcRIIa and FCcRIIIa polymorphisms was
observed in these patients [12].
Since the approval of brentuximab vedotin,
two confirmed cases and one suspected case of
progressive multifocal leukoencephalopathy
(PML) were reported [24], and patients with
new-onset central nervous system abnormalities
should be evaluated promptly. Due to the
serious nature of PML a new ‘‘Boxed Warning’’
highlighting this potential risk was added to the
drug label [25]. PML has been observed with the
use of other mAbs, especially with rituximab.
Although with the latter, a possible B cell
depletion and consequent immunosuppression
can play a causative role, it is known that
activated B- and T cells express CD30, and an
anti-CD30 therapy can possibly lead to
dysregulation of the immune system.
CURRENT STUDIES AND FUTURE
DIRECTIONS
Based on the encouraging results from phase 2
studies, brentuximab vedotin is currently being
investigated in different disease settings. Given
the high response rate in the relapsed setting
and the manageable toxicity profile,
incorporating brentuximab vedotin into first-
line therapy represents an attractive option.
Ansell et al. [23] recently presented the interim
results of a phase 1 study of brentuximab
vedotin combined with ABVD or AVD
(doxorubicin, vinblastine, dacarbazine) in
patients with newly diagnosed advanced-stage
cHL. In total, 47 patients were evaluated after
treatment, and only 7 patients had to
discontinue therapy due to adverse events.
Bleomycin was discontinued in 11 patients
due to pulmonary toxicity, and all other
adverse events were mild and manageable. The
objective response was 96%, with 21 of 22
patients in the ABVD and 23 of 25 patients in
the AVD group achieving a CR.
Multiple studies are being conducted with
brentuximab in different scenarios. A phase 3
trial of brentuximab vedotin combined with
AVD versus ABVD is being planned. In addition,
a phase 3 placebo-controlled trial is evaluating
the efficacy of brentuximab vedotin given as
maintenance therapy in high-risk patients after
ASCT. An estimated 322 patients completed
accrual and will receive best supportive care
following ASCT plus either brentuximab
vedotin 1.8 mg/kg every 3 weeks, or placebo.
Gopal et al. [26] recently showed that
brentuximab vedotin is safe in patients
relapsing after allogeneic SCT, with clinical
responses in 50% of patients, and modest
adverse events.
Brentuximab vedotin is also being tested in
other CD30? nonlymphomatous malignancies
[27], T/NK lymphomas [28] and in steroid-
refractory graft versus host disease [29].
DISCUSSION
The introduction of a safe and effective anti-
CD30 ADC has written another chapter in one
of the most successful histories in modern
oncology. HL, previously a lethal disease, is
now highly curable when treated with multi-
agent chemotherapy regimens, with or without
20 Biol Ther (2013) 3:15–23
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radiation therapy. For those patients not
responding to first-line therapy, high-dose
chemotherapy followed by ASCT can cure
almost 50% of patients [5]. However, a
fraction of patients will not benefit from this
strategy, in particular patients with primary
refractory or chemoresistant disease, and those
not eligible for ASCT.
The challenge in making a successful history
more successful has led to intense research in
cHL, especially in the relapse/refractory setting.
Moreover, the fact that conventional
chemotherapy may fail to eradicate the disease,
and that the interaction between HRS and the
surrounding stroma may play a major role, have
brought new targets to attention. Histone
deacetylase inhibitors [30], mammalian
target of rapamycin inhibitors [31], and
immunomodulatory agents [32] have shown
promising results. Furthermore, rituximab has
shown activity in cHL, regardless of CD20
expression by HRS, possibly by targeting the
reactive B-cells which support the HRS cells [33].
CD30 represents the most attractive target in
cHL, given the uniform and strong expression
on tumor cells and the limited expression in
normal tissues. However, early phase 1–2
clinical trials with ‘‘naked’’ anti-CD30 were
disappointing, with almost no objective
clinical responses.
The idea of using an ADC to selectively deliver
cytotoxic drugs to the target malignant cells, like
a ‘‘Trojan horse,’’ is very interesting, and has been
proved possible with the anti-CD33 ADC
gemtuzumab ozogamicin. Studies with the
novel ADC brentuximab vedotin demonstrated
impressive clinical efficacy in heavily pretreated
patients.These results areevenmore impressive if
we consider that these patients have failed an
ASCT. Moreover, these results represent proof of
principle that the ADC methodology can
overcome some factors that have limited the
efficacy of conventional immunotherapy in cHL.
Furthermore, the response rates observed with
brentuximab vedotin are superior to other novel
single agents [30–32].
The prognosis of patients with sALCL treated
with conventional therapy is relatively poor,
especially if the disease is ALK-negative. For
these patients, the benefit of ASCT as salvage
therapy is even more subtle, and patients not
achieving a CR or at least a good PR before ASCT
usually have poor prognosis. Moreover, patients
failing ASCT have few options. New drugs have
received accelerated approvals from the FDA for
treatment of relapsed/refractory peripheral T
cell lymphoma, including ALCL. However, in
phase 2 trials that preceded the approval of
these drugs (pralatrexate and romidepsin), the
ORR rates were less than 30%, with less than
15% of patients achieving a CR [34, 35].
Thus, the options for ALCL patients failing
first-line treatment are even scarcer, with
inferior outcomes. Therefore, brentuximab
vedotin has proven the best option for those
patients, even before ASCT, especially when less
than a CR is achieved by salvage therapy. For
those patients, brentuximab vedotin is a
rational bridge before transplant.
Finally, the next step when treating cHL and
ALCL patients in CR after treatment with
brentuximab vedotin is unclear. Although
allogeneic transplant is possible, retreatment
may also be possible. In a case series, patients
with CD30? malignancies underwent
retreatment, and objective responses were
observed in six of eight patients [36].
CONCLUSION
Brentuximab vedotin is an anti-CD30 ADC with
proven efficacy in patients with relapsed or
refractory HL and relapsed or refractory sALCL.
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Other CD30? malignancies have also shown
response in case reports/series. Due to a
favorable toxicity profile, brentuximab vedotin
is now an excellent option for HL failing an
ASCT and for ALCL patients after one prior
course of multi-agent chemotherapy regimen.
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